{"nctId":"NCT02207088","briefTitle":"Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","startDateStruct":{"date":"2014-09-23","type":"ACTUAL"},"conditions":["Chronic Hepatitis C","Hepatitis C Virus","Compensated Cirrhosis","Severe Renal Impairment","End-stage Renal Disease"],"count":68,"armGroups":[{"label":"3-DAA (Direct Acting Antivirals) with or without RBV","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir","Drug: dasabuvir","Drug: Ribavirin"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir","otherNames":["ABT-450/r/ABT-267","Viekira Pak","paritaprevir also known as ABT-450","ombitasvir also known as ABT-267","dasabuvir also known as ABT-333"]},{"name":"dasabuvir","otherNames":["ABT-333"]},{"name":"Ribavirin","otherNames":["RBV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Positive for anti-HCV Ab (Antibody) and HCV RNA \\>1,000 IU/mL at Screening.\n2. Screening laboratory result indicating HCV genotype 1 infection.\n3. Subject has never received antiviral treatment for hepatitis C infection (treatment-naive subject) or subject has received previous treatment with peginterferon with or without RBV with non-response (HCV RNA quantifiable at end of treatment or relapsed after end of treatment).\n4. Estimated Glomerular Filtration Rate (eGFR) \\< 30 mL/min/1.73 m\\^2 as estimated by the Modification of Diet in Renal Disease (MDRD) method.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding.\n2. Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency Virus (HIV Ab).\n3. Any current or past clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation such as ascites (noted on physical exam), variceal bleeding, or hepatic encephalopathy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\\<LLOQ) 12 weeks after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \\< LLOQ during treatment, confirmed increase of \\> 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-Treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \\< LLOQ at the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":68},"commonTop":["ANAEMIA","FATIGUE","DIARRHOEA","NAUSEA","VOMITING"]}}}